February 2026 Research Update

This month strengthened a simple message: testing pathways can miss Fabry disease in females, and combining genetic testing with family-based follow-up finds more people.

Across screening studies, genetic testing repeatedly found more Fabry disease in females than enzyme-only approaches, which can look normal even when Fabry is present. [1] This matters because missed diagnoses delay family screening and can postpone recognition of organ involvement. [2]

In high-risk women (for example, after unexplained stroke or heart findings), a large meta-analysis reported that Fabry disease was uncommon but present, and it was detected more often when genetic testing was used rather than enzyme-based testing. [1] The practical meaning is that women may need a different diagnostic approach than men, because enzyme levels can be less reliable in females. [1]

Real-world newborn screening data showed a striking sex gap: in Tennessee, screening identified males but did not identify any females with Fabry disease during the years studied. [2] Many females were instead identified later through cascade testing after a son was detected, or because symptoms or family history led to testing. [2]

A pilot program in one region of China reported that combining high-risk screening with family screening increased the number of diagnoses, with many carrying the same regional GLA variant. [3] The report also showed that some females in this group had normal or only mildly abnormal enzyme or blood markers, which fits with the broader concern that single-step testing can miss cases. [3]

In a pediatric registry from China, diagnosis often happened around late childhood and delays of several years were common, while family screening accounted for a large share of diagnoses in girls. [4] This adds to the pattern that family-based testing is a major pathway to finding Fabry disease earlier, especially for females and children with less obvious early symptoms. [4]

What this means in everyday terms

These studies mainly add clarity about diagnosis rather than changing treatments. They support the idea that females can be under-detected when testing relies heavily on enzyme activity, and that genetic and family-based testing pathways identify additional people with Fabry disease. This matters now because being correctly identified is the first step for family members to be offered testing and for symptoms to be interpreted in the right context, but the studies do not define a single best testing strategy for every situation.

What remains uncertain is how often each approach finds people with different Fabry variants in different countries, and how newborn screening programs might be adjusted to reduce the female detection gap. The screening studies also do not show how earlier identification changes long-term health outcomes, since they focus on detection rather than follow-up results. [1]

This month added two complementary pieces: early evidence that add-on kidney-protective medicines may lower protein loss in urine, and clearer information about which heart and kidney measurements relate to later serious heart events.

In a small 12-month observational study, adding dapagliflozin (a drug often used for kidney and heart protection) to stable Fabry-specific therapy was linked with lower albumin in the urine while kidney filtration stayed similar over time. [5] This is an early signal rather than proof, because there was no comparison group and only 16 people were included. [5]

A single-patient report also described improved and more stable kidney lab markers after adding a nonsteroidal mineralocorticoid receptor antagonist to ongoing enzyme replacement therapy. [6] Because this is one person, it mainly highlights a possible approach being explored rather than a reliable expectation for others. [6]

For longer-term cardiovascular risk, a large adult cohort study reported that serious heart and stroke-related events occurred in a minority of patients over years of follow-up, and were more common in males. [7] Older age, worse kidney filtration, longer QRS on ECG (a measure of heart electrical conduction), and higher heart muscle mass were among the measurements that predicted higher event risk in that dataset. [7]

What this means in everyday terms

The kidney findings may matter in the future if confirmed, because reducing protein leakage into urine is often used as a sign of better kidney stability. Right now, the strongest new information is that these add-on approaches are being studied in Fabry disease and have early real-world signals, but the evidence is still limited. The heart-outcomes study may matter now for understanding prognosis, because it links everyday measurements like kidney filtration and ECG findings with the chance of major heart or stroke events over time. [7]

Uncertainty remains about how well dapagliflozin or similar add-on approaches work across different Fabry subtypes and over longer periods, since the available study was small and short. [5] The cardiovascular risk estimates also come from routine-care data, so they describe patterns seen in that cohort rather than guaranteeing what will happen for any one person. [7]

This month highlighted how Fabry disease can be mistaken for other conditions, overlap with other rare disorders, or be best recognized with specific heart imaging and genetic testing.

Two imaging-based studies comparing Fabry-related heart thickening with hypertrophic cardiomyopathy reported a consistent pattern: Fabry disease tended to show lower native T1 values on cardiac MRI and a typical scar pattern in the basal inferolateral wall. [8] In one study focused on a specific Fabry mutation, a septal native T1 cutoff separated Fabry from hypertrophic cardiomyopathy with high sensitivity and specificity in that dataset. [9]

A separate study applied an existing Fabry cardiomyopathy staging algorithm and found that staging depended on having both echocardiography and cardiac MRI available, with electrical and imaging measures shifting as stages increased. [10] The value of this work is mainly organizational: it shows how imaging features cluster by stage, but it did not test whether the stages predict future outcomes in this cohort. [10]

Case reports reinforced that Fabry diagnosis sometimes emerges from unusual presentations or competing explanations. One man with chest pain had ECG changes that looked like a heart attack, but testing did not show blocked arteries and Fabry was confirmed by enzyme, lyso-Gb3, and genetics. [11] Another man was diagnosed after evaluation for shoulder pain and later started migalastat, with some blood markers improving while imaging did not show clear progression at follow-up. [12]

Other case reports emphasized dual diagnoses and look-alike findings. One child had Fabry disease alongside atypical hemolytic uremic syndrome history and a separate inherited heart muscle gene change, with kidney function worsening despite enzyme replacement therapy over 2 years. [13] Another adult had a neurological genetic condition plus a GLA variant with a subclinical Fabry picture, showing how broad genetic testing can uncover more than one rare explanation in the same person. [14]

Not every classic biopsy clue points to Fabry disease: one report described zebra bodies on kidney electron microscopy in LCAT deficiency, with normal Fabry enzyme testing and negative Fabry genetics. [15] This adds a reminder that biopsy patterns can overlap across rare diseases, so confirmation testing matters. [15]

What this means in everyday terms

These studies mainly add understanding about diagnosis and interpretation, not treatment choices. They show that certain cardiac MRI patterns can help distinguish Fabry-related heart thickening from other causes, and that genetic testing can be important when symptoms are atypical or when more than one rare disorder may be present. The case reports also show that Fabry can be confused with other diseases or even mimic a heart attack pattern on ECG, which can affect how quickly the right diagnosis is considered. [11]

What remains uncertain is how well the MRI cutoffs and staging approach perform across different hospitals, scanners, and Fabry variants, since the studies were retrospective and often focused on specific regional mutations. [9] Case reports are useful for awareness, but they cannot predict what will happen for most people with Fabry disease. [13]

This month made physical functioning feel more measurable: classic Fabry, especially in males, was linked with lower exercise capacity and muscle mass, while a proposed urine marker showed no clear relationship to kidney measures in a small study.

In an adult cross-sectional study, reduced exercise capacity was more common in people with classic Fabry disease than in late-onset or uncertain-variant groups, and classic males showed weaker grip strength and worse chair-stand performance. [16] The study also reported that a body-composition measure called phase angle tracked closely with peak exercise capacity, suggesting it may reflect overall physical condition in Fabry disease. [16]

Fatigue scores were higher in the classic phenotype and were also higher in treated than untreated participants in this snapshot in time. [16] Because treatment is often started in people with more severe disease, the study cannot tell whether treatment increased fatigue, but it does underline that fatigue remains a major issue even among people receiving Fabry-specific therapy. [16]

A small urine-marker pilot study tested VEGF-A165b mRNA as a possible sign of kidney involvement in Fabry disease, but it was not clearly different from healthy controls and did not track with urine albumin or kidney filtration. [17] The only reported link was with time on enzyme replacement therapy, which is interesting but hard to interpret without longer follow-up and larger samples. [17]

What this means in everyday terms

These findings may matter most for understanding day-to-day impact and for future research that tries to measure it better. The fitness study suggests that exercise capacity and muscle-related measures can capture differences between classic and later-onset Fabry, and it helps validate fatigue as a real and measurable part of the condition. The urine-marker study is early research, and it does not yet provide a new test that can reliably track Fabry kidney disease. [17]

Uncertainty remains because both studies were cross-sectional snapshots, so they cannot show how these measures change over time or whether changing treatment changes them. Larger and longer studies are needed to learn whether phase angle or urine VEGF-A165b becomes useful for monitoring. [16]